330 related articles for article (PubMed ID: 32534790)
1. Advanced Prostate Cancer: Treatment Advances and Future Directions.
Swami U; McFarland TR; Nussenzveig R; Agarwal N
Trends Cancer; 2020 Aug; 6(8):702-715. PubMed ID: 32534790
[TBL] [Abstract][Full Text] [Related]
2. New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?
van Dodewaard-de Jong JM; Verheul HMW; Bloemendal HJ; de Klerk JMH; Carducci MA; van den Eertwegh AJM
Clin Genitourin Cancer; 2015 Aug; 13(4):271-279. PubMed ID: 25704270
[TBL] [Abstract][Full Text] [Related]
3. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
4. Clinical case of a patient undergoing radium-223 treatment following treatment with abiraterone acetate and enzalutamide.
Jiménez Romero ME; Díez Farto S; Navarro Serrato JS; Canelón Castillo E; Revelo Cadena I
Exp Oncol; 2018 Jun; 40(2):144-148. PubMed ID: 29949528
[TBL] [Abstract][Full Text] [Related]
5. Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies.
Crawford ED; Higano CS; Shore ND; Hussain M; Petrylak DP
J Urol; 2015 Dec; 194(6):1537-47. PubMed ID: 26196735
[TBL] [Abstract][Full Text] [Related]
6. Clinically Lymph Node Positive Prostate Cancer: At the Intersection of Focal and Systemic Disease Control.
Reichert ZR; Dess RT
Cancer J; 2020; 26(1):53-57. PubMed ID: 31977386
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Primary in Metastatic Prostate Cancer: What Is the Standard of Care?
Joseph N; Anjanappa M; Choudhury A
Cancer J; 2020; 26(1):83-86. PubMed ID: 31977390
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of metastatic, castration-resistant prostate cancer].
von Amsberg G; Merseburger AS
Urologe A; 2020 Jun; 59(6):673-679. PubMed ID: 32274540
[TBL] [Abstract][Full Text] [Related]
9. [Integration of drug treatment in the management concept of prostate cancer].
Cathomas R
Internist (Berl); 2013 Oct; 54(10):1262-70. PubMed ID: 23896735
[TBL] [Abstract][Full Text] [Related]
10. New perspectives in the therapy of castration resistant prostate cancer.
Rescigno P; Buonerba C; Bellmunt J; Sonpavde G; De Placido S; Di Lorenzo G
Curr Drug Targets; 2012 Dec; 13(13):1676-86. PubMed ID: 23043326
[TBL] [Abstract][Full Text] [Related]
11. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology.
Nuhn P; De Bono JS; Fizazi K; Freedland SJ; Grilli M; Kantoff PW; Sonpavde G; Sternberg CN; Yegnasubramanian S; Antonarakis ES
Eur Urol; 2019 Jan; 75(1):88-99. PubMed ID: 29673712
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in Prostate Cancer Treatment and Drug Discovery.
Nevedomskaya E; Baumgart SJ; Haendler B
Int J Mol Sci; 2018 May; 19(5):. PubMed ID: 29734647
[TBL] [Abstract][Full Text] [Related]
13. The Evolving Systemic Treatment Landscape for Patients with Advanced Prostate Cancer.
Pagliuca M; Buonerba C; Fizazi K; Di Lorenzo G
Drugs; 2019 Mar; 79(4):381-400. PubMed ID: 30742279
[TBL] [Abstract][Full Text] [Related]
14. Current management of advanced and castration resistant prostate cancer.
Gomella LG; Petrylak DP; Shayegan B
Can J Urol; 2014 Apr; 21(2 Supp 1):1-6. PubMed ID: 24775717
[TBL] [Abstract][Full Text] [Related]
15. PARP inhibitors in castration-resistant prostate cancer.
Tripathi A; Balakrishna P; Agarwal N
Cancer Treat Res Commun; 2020; 24():100199. PubMed ID: 32745972
[TBL] [Abstract][Full Text] [Related]
16. Cabazitaxel rechallenge at prostate-specific antigen relapse after previous cabazitaxel and docetaxel chemotherapy: case report.
Perry CJ; Sundar S
Clin Genitourin Cancer; 2012 Sep; 10(3):207-9. PubMed ID: 22445962
[No Abstract] [Full Text] [Related]
17. Castration resistant prostate cancer (CRPC): state of the art, perspectives and new challenges.
Massari F; Maines F; Modena A; Brunelli M; Bria E; Artibani W; Martignoni G; Tortora G
Anticancer Agents Med Chem; 2013 Jul; 13(6):872-86. PubMed ID: 23272970
[TBL] [Abstract][Full Text] [Related]
18. The Winds of Change: Emerging Therapeutics in Prostate Cancer.
Pezaro CJ; Marciscano AE; Madan RA
Am Soc Clin Oncol Educ Book; 2018 May; 38():382-390. PubMed ID: 30231379
[TBL] [Abstract][Full Text] [Related]
19. Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors.
Criscuolo D; Morra F; Giannella R; Cerrato A; Celetti A
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31242618
[TBL] [Abstract][Full Text] [Related]
20. Management of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC): an Evolving Treatment Paradigm.
Weiner AB; Nettey OS; Morgans AK
Curr Treat Options Oncol; 2019 Jul; 20(9):69. PubMed ID: 31286275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
